

CITATION REPORT

List of articles citing

Quantification of lean bodyweight

DOI: 10.2165/00003088-200544100-00004
Clinical Pharmacokinetics, 2005, 44, 1051-65.

Source: <https://exaly.com/paper-pdf/39421321/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
654	Clinical Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 645-647	6.2	1
653	Optimal designs for studying bioimpedance. 2007 , 28, 1465-83		9
652	Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. 2007 , 25, 4707-13		123
651	Dosing in obesity: a simple solution to a big problem. 2007 , 82, 505-8		187
650	The lasso--a novel method for predictive covariate model building in nonlinear mixed effects models. 2007 , 34, 485-517		45
649	Does saturable formation of gemcitabine triphosphate occur in patients?. 2008 , 63, 55-64		18
648	Lean body mass normalizes the effect of obesity on renal function. 2008 , 65, 964-5		53
647	Individualized compared with conventional dosing of enoxaparin. 2008 , 83, 882-8		29
646	Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. 2008 , 65, 502-10		44
645	Mechanism-based concepts of size and maturity in pharmacokinetics. 2008 , 48, 303-32		774
644	Letters to the Editor. 2008 , 38, 77-81		
643	Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. 2008 , 30, 490-6		70
642	Mechanistic basis of using body size and maturation to predict clearance in humans. 2009 , 24, 25-36		344
641	Human renal function maturation: a quantitative description using weight and postmenstrual age. 2009 , 24, 67-76		349
640	Encouraging the move towards predictive population models for the obese using propofol as a motivating example. 2009 , 26, 1626-34		29
639	Informative study designs to identify true parameter-covariate relationships. 2009 , 36, 147-63		15
638	[Target-controlled infusion. Clinical relevance and special features when using pharmacokinetic models]. 2009 , 58, 708-15		10

637	Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. 2009 , 68, 700-11		17
636	Response to Influence of Lean Body Weight on Anticancer Drug Clearance 2009 , 85, 24-24		5
635	Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. 2009 , 63, 1050-7		97
634	Estimation of creatinine clearance in morbidly obese patients. 2009 , 66, 642-8		120
633	Pharmacokinetic model-driven remifentanyl administration in the morbidly obese: the 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem?. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 397-8	6.2	20
632	Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 477-87	6.2	8
631	Pharmacokinetics in special populations. 2009 , 41, 422-54		15
630	Total intravenous anaesthesia to obese patients: largely guesswork?. 2009 , 26, 359-61		18
629	Population pharmacokinetics of valsartan in pediatrics. 2009 , 24, 145-52		10
628	Drug disposition in obesity and protein-energy malnutrition. 2010 , 69, 543-50		25
627	Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. 2010 , 32, 482-8		12
626	First-dose pharmacokinetics of lithium carbonate in children and adolescents. 2010 , 30, 404-10		24
625	Perioperative pharmacology in morbid obesity. 2010 , 23, 485-91		53
624	Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics. 2010 , 203, 254.e1-12		25
623	Low serum creatinine is associated with type 2 diabetes in morbidly obese women and men: a cross-sectional study. 2010 , 10, 6		33
622	Estimation of lean body weight in older community-dwelling men. 2010 , 69, 118-27		16
621	Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey. 2010 , 69, 520-8		16
620	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. 2010 , 69, 484-97		53

619	Dosing in children. 2010 , 87, 367-70		55
618	Pediatric models for adult target-controlled infusion pumps. 2010 , 20, 223-32		52
617	Positioning. 85-91		
616	Effects of obesity on anesthetic agents. 100-110		
615	Effect of increased body mass index and anaesthetic duration on recovery of protective airway reflexes after sevoflurane vs desflurane. 2010 , 104, 175-82		73
614	Dose adjustment of anaesthetics in the morbidly obese. 2010 , 105 Suppl 1, i16-23		272
613	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1275-82	5.9	40
612	Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren. 2010 , 50, 1358-66		14
611	Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. 2010 , 105, 448-56		127
610	Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3635-40	5.9	53
609	Estimating the glomerular filtration rate in obese adult patients for drug dosing. 2010 , 17, e53-62		87
608	Acute kidney injury in the critically ill, morbidly obese patient: diagnostic and therapeutic challenges in a unique patient population. 2010 , 26, 607-24		13
607	Predictive performance of the 'Minto' remifentanyl pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 131-9	6.2	34
606	Effect of obesity on the pharmacokinetics of drugs in humans. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 71-87	6.2	482
605	Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. 2010 , 24, 23-39		150
604	Adjustment of dosing of antimicrobial agents for bodyweight in adults. 2010 , 375, 248-51		108
603	Gestione perioperatoria del paziente obeso. 2011 , 16, 1-10		
602	The effects of obesity on drug pharmacokinetics in humans. 2011 , 7, 697-706		67

601	Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 739-50	6.2	56
600	Implications of obesity for drug therapy: limitations and challenges. 2011 , 90, 77-89		140
599	Manejo perioperatorio del paciente obeso. 2011 , 37, 1-11		
598	Introduction to obesity. 1-11		
597	Fat-free weight prediction in morbidly obese females. 2011 , 4, 149-55		3
596	A comparison of folic acid pharmacokinetics in obese and nonobese women of childbearing age. 2011 , 33, 336-40		26
595	Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. 2011 , 113, 57-62		98
594	Anesthetizing the obese. 2011 , 113, 1-3		14
593	Prise en charge pharmacologique du patient obèse. 2011 , 8, 1-10		
592	Tips and traps analyzing pediatric PK data. 2011 , 21, 222-37		116
591	How reliable is eGFR when calculating drug dosage in acute medical admissions?. 2011 , 41, 327-31		2
590	Gentamicin pharmacokinetics in old age and frailty. 2011 , 71, 224-31		37
589	Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects. 2011 , 72, 985-9		7
588	Anticoagulating obese patients in the modern era. 2011 , 155, 137-49		75
587	Pharmacokinetic considerations in the obese. 2011 , 25, 27-36		71
586	A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. 2011 , 68, 1233-41		14
585	Antifungal Dosing in Obesity: A Review of the Literature. 2011 , 5, 83-91		4
584	Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. 2011 , 11, 3		33

583	The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. 2011 , 11, 5		6
582	A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. 2011 , 117, 4732-9		18
581	A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. 2011 , 33, 711-8		33
580	Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 5238-42	5.9	55
579	Antibiotic dosing in multiple organ dysfunction syndrome. 2011 , 139, 1210-1220		70
578	A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions. 2011 , 39, 1278-87		16
577	Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). 2011 , 66, 2083-91		24
576	Pharmacokinetics and tissue penetration of ceftiofloxacin in obesity: implications for risk of surgical site infection. 2011 , 113, 730-7		77
575	Comparable population pharmacokinetics and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2927-36	5.9	10
574	Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 4006-11	5.9	56
573	Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2601-5	5.9	38
572	An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. 2012 , 18, 323-32		11
571	Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3857-63	5.9	31
570	Dosing of antibiotics in obesity. 2012 , 25, 634-49		100
569	Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 715-24	5.9	14
568	Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3864-72	5.9	69
567	Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. 2012 , 67, 1996-2004		27
566	Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. 2012 , 109, 551-60		11

565	Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. 2012 , 1, e4		20
564	The effect of obesity on the ED(95) of propofol for loss of consciousness in children and adolescents. 2012 , 115, 147-53		40
563	Individualized dosing with anesthetic agents. 2012 , 92, 417-9		6
562	Drug Dosing in the Critically Ill Obese Patient. 2012 , 195-207		2
561	Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study. 2012 , 7, 1053-7		10
560	The pharmacokinetics of oxypurinol in people with gout. 2012 , 74, 477-89		22
559	Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 543-551	6.2	50
558	The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. 2012 , 46, 317-28		28
557	Obesity and Nutrition Disorders. 2012 , 215-224		
556	Augmented renal clearance in the critically ill: how to assess kidney function. 2012 , 46, 952-9		58
555	Drug-nutrient interactions: a broad view with implications for practice. 2012 , 112, 506-17		50
554	The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. 2012 , 115, 823-9		15
553	Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. 2012 , 32, 856-68		105
552	Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin. 2012 , 74, 797-805		19
551	Allometric or lean body mass scaling of propofol pharmacokinetics: towards simplifying parameter sets for target-controlled infusions. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 137-45	6.2	20
550	The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 319-30	6.2	108
549	Underdosing of common antibiotics for obese patients in the ED. 2012 , 30, 1212-4		28
548	Perioperative management of the severely obese patient: a selective pathophysiological review. 2012 , 59, 974-96		55

547	Polypharmacy and food-drug interactions among older persons: a review. 2012 , 31, 325-403	33
546	Early sorafenib-induced toxicity is associated with drug exposure and UGT1A9 genetic polymorphism in patients with solid tumors: a preliminary study. 2012 , 7, e42875	75
545	How do I Adjust Antimicrobial Daily Dosage in Patients with MODS? A Pharmacist's Contribution. 2012 , 199-217	
544	Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. 2012 , 67, 1305-10	61
543	Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. 2012 , 32, 604-12	103
542	Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients. 2012 , 22, 791	11
541	Estimation of lean body weight in older women with hip fracture. 2012 , 16, 188-92	7
540	Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. 2012 , 68, 961-8	32
539	My child is unique; the pharmacokinetics are universal. 2012 , 22, 530-8	31
538	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal. 2012 , 10, 500-2; author reply 502-4	2
537	Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. 2012 , 73, 758-67	14
536	Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology. 2012 , 73, 685-90	28
535	The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. 2013 , 69, 1411-21	24
534	Lean-scaled weight: a proposed weight scalar to calculate drug doses for obese patients. 2013 , 60, 214-5	16
533	Drug and nutrition interactions: not just food for thought. 2013 , 38, 269-71	25
532	A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors. 2013 , 71, 991-8	5
531	A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors. 2013 , 71, 21-7	9
530	Anesthetic Pharmacology and the Morbidly Obese Patient. 2013 , 3, 10-17	17

529	Unraveling Pharmacokinetics and Pharmacodynamics in Infants and Children. 2013 , 3, 27-36		
528	A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 475-85	6.2	13
527	Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 373-84	6.2	84
526	Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children. 2013 , 65, 107-21		10
525	Reply to Pai. 2013 , 57, 1786		2
524	Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome. 2013 , 21, 1753-8		15
523	Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. 2013 , 26, 1198-207		51
522	A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma. 2013 , 31, 145-51		10
521	Lessons from providing total intravenous anesthesia (TIVA) to a morbidly obese patient (294 kg [648 lbs], body mass index 85.5 kg/m ²). 2013 , 25, 428-429		1
520	Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. 2013 , 57, 524-31		263
519	Rational development and utilization of antibody-based therapeutic proteins in pediatrics. 2013 , 137, 225-47		45
518	Appendicitis in obese children. 2013 , 29, 537-44		16
517	Objectifs pharmacocinétiques, pharmacodynamiques (PK/PD) et adaptation posologique des antibiotiques chez le patient de réanimation : vers une approche pratique. 2013 , 83-103		
516	Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 289-301	6.2	47
515	Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. 2013 , 76, 932-8		26
514	Understanding dosing: children are small adults, neonates are immature children. 2013 , 98, 737-44		118
513	Body composition in older community-dwelling adults with hip fracture: portable field methods validated by dual-energy X-ray absorptiometry. 2013 , 109, 1219-29		10
512	The performances of the Cockcroft-Gault, modification of diet in renal disease study and chronic kidney disease epidemiology collaboration equations in predicting gentamicin clearance. 2013 , 50, 546-57		18

511	Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. 2013 , 57, 1568-76		97
510	BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin. 2013 , 37, 1771-8		6
509	Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1144-9	5.9	50
508	Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects?. 2013 , 68, 666-73		31
507	Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5889-900	5.9	14
506	Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. 2013 , 68, 1338-47		16
505	Comparing dose prediction software used to manage gentamicin dosing. 2013 , 43, 519-25		10
504	An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. 2013 , 2, e73		15
503	Lean body mass: the development and validation of prediction equations in healthy adults. 2013 , 14, 53		16
502	Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010. 2013 , 10, 1665-73		9
501	Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. 2014 , 210, 146-53		87
500	Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 931-41	6.2	61
499	Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 919-30	6.2	34
498	Covariates of intravenous paracetamol pharmacokinetics in adults. 2014 , 14, 77		36
497	Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 136-43	5.9	27
496	Comments on linezolid in morbid obesity. 2014 , 48, 429		
495	Dose scaling for the morbidly obese. 2014 , 20, 69-72		1
494	A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. 2014 , 24, 1759-64		25

493	A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. 2015 , 70, 1166-74		18
492	Perioperative management for the obese outpatient. 2014 , 27, 576-82		12
491	Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. 2014 , 20, 754-63		94
490	Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. 2014 , 119, 302-310		61
489	Resveratrol does not benefit patients with nonalcoholic fatty liver disease. 2014 , 12, 2092-103.e1-6		198
488	Importance of hematocrit for a tacrolimus target concentration strategy. 2014 , 70, 65-77		72
487	Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 373-83	6.2	36
486	The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. 2014 , 70, 549-55		41
485	Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. 2014 , 69, 190-9		21
484	Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. 2014 , 69, 715-23		86
483	Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥ 40 kg/m ²) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 753-62	6.2	23
482	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. 2014 , 78, 509-23		58
481	Comparison of the probability of target attainment of anidulafungin against <i>Candida</i> spp. in patients with acute leukaemia. 2014 , 44, 450-7		8
480	Pharmacokinetics of caspofungin in ICU patients. 2014 , 69, 3294-9		52
479	Optimum lean body formulation for correction of standardized uptake value in PET imaging. 2014 , 55, 1481-4		69
478	Amikacin dosing in the ICU: we now know more, but still not enough. 2014 , 40, 1033-5		3
477	Perioperative fluid guidance with transthoracic echocardiography and pulse-contour device in morbidly obese patients. 2014 , 24, 2117-25		14
476	Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 479-88	6.2	24

475	Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. 2014 , 14, 97		24
474	Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 943-57 ^{6.2}		5
473	Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. 2014 , 78, 178-87		17
472	The effect of bariatric surgery on renal function. 2014 , 10, 808-13		26
471	Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review. 2014 , 6, 227-33		10
470	The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia. 2015 , 100, 62-9		19
469	Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients. 2015 , 4, 362-71		12
468	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. 2015 , 99, 2158-66		60
467	Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents. 2015 , 25, 911-923		22
466	Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. 2015 , 80, 1185-96		32
465	Atropine sulfate for treatment of bradycardia in a patient with morbid obesity: what may happen when you least expect it. 2015 , 2015,		4
464	Prediction of Fat-Free Mass in Children. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1169-78	6.2	77
463	Peri-operative management of the obese surgical patient 2015: Association of Anaesthetists of Great Britain and Ireland Society for Obesity and Bariatric Anaesthesia. 2015 , 70, 859-76		148
462	Optimal Drug Dosing in the Obese--Still Many Years Ahead. 2015 , 25, 2159-60		1
461	Effect of age and sex on lacosamide pharmacokinetics in healthy adult subjects and adults with focal epilepsy. 2015 , 35, 255-65		10
460	Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. 2015 , 25, 628-34		23
459	Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. 2015 , 33, 257-68		40
458	FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. 2015 , 42, 328-54		1446

457	Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study. 2015 , 37, 1340-51		19
456	Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. 2015 , 35, 127-39		56
455	Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage. 2015 , 24, 12-7		13
454	A Review of the Toxicologic Implications of Obesity. 2015 , 11, 342-54		18
453	Lean Body Weight Is Not a Weight Scalar for Estimating Drug Doses in Morbid Obesity. 2015 , 25, 1496-7		5
452	Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. 2015 , 71, 25-34		12
451	Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. 2015 , 42, 163-77		28
450	Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment. 2015 , 42, 225-36		8
449	Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4403-9	5.9	40
448	Feasibility of closed-loop co-administration of propofol and remifentanyl guided by the bispectral index in obese patients: a prospective cohort comparison. 2015 , 114, 605-14		25
447	The weight debate. 2015 , 16, 234-238		4
446	Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 933-44	6.2	23
445	Dexmedetomidine pharmacokinetics in the obese. 2015 , 71, 1501-8		40
444	The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. 2015 , 32, 3927-36		43
443	Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5681-96	5.9	50
442	Risk factors for polyuria in a cross-section of community psychiatric lithium-treated patients. 2015 , 17, 50-62		7
441	Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity. 2015 , 21, 513-20		18
440	A nutrition strategy for obese ICU patients with special consideration for the reference of protein. 2015 , 10, e160-e166		5

439	Effect of 1-h moderate-intensity aerobic exercise on intramyocellular lipids in obese men before and after a lifestyle intervention. 2015 , 40, 1262-8		13
438	Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6241-7	5.9	17
437	Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3956-65	5.9	21
436	Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing. 2015 , 37, 1897-923		46
435	Drug disposition in obesity: toward evidence-based dosing. 2015 , 55, 149-67		79
434	Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 409-21	6.2	26
433	Spectral Gini Index for Quantifying the Depth of Consciousness. 2016 , 2016, 2304356		4
432	Prediction of Fat-Free Mass in Kidney Transplant Recipients. 2016 , 38, 439-46		3
431	Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 4585-9	5.9	17
430	Best anaesthetic drug strategy for morbidly obese patients. 2016 , 29, 119-28		26
429	Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose. 2016 , 30, 108-13		4
428	Appropriate dosing of sugammadex to reverse deep rocuronium-induced neuromuscular blockade in morbidly obese patients. 2016 , 71, 265-72		33
427	Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. 2016 , 82, 762-72		7
426	Predicting allopurinol response in patients with gout. 2016 , 81, 277-89		33
425	Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. 2016 , 44, 2079-2103		158
424	Evaluation of CT-based SUV normalization. 2016 , 61, 6369-83		4
423	Perioperative complications of obese patients. 2016 , 22, 401-5		4
422	Assessment of inpatient admissions and top 25 medications for obese pediatric patients at two academic hospitals. 2016 , 73, 1243-9		7

421	Additional Factors Affecting Plasma Concentrations. 2016 , 211-232		
420	The Population Pharmacokinetics of D-Hydroxybutyrate Following Administration of (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate. 2016 , 18, 678-88		36
419	Estimating the induction dose of propofol in morbid obesity: striking a happy medium. 2016 , 116, 730-1		3
418	The Impact of Model-Misspecification on Model Based Personalised Dosing. 2016 , 18, 1244-1253		3
417	Pharmacokinetic and Pharmacodynamic Evaluation of a Weight-Based Dosing Regimen of Cefoxitin for Perioperative Surgical Prophylaxis in Obese and Morbidly Obese Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5885-93	5.9	15
416	Morbid Obesity Alters Both Pharmacokinetics and Pharmacodynamics of Propofol: Dosing Recommendation for Anesthesia Induction. 2016 , 44, 1579-83		25
415	Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. 2016 , 81, 1103-12		15
414	Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. 2016 , 81, 113-23		17
413	Review of commonly used age-based weight estimates for paediatric drug dosing in relation to the pharmacokinetic properties of resuscitation drugs. 2016 , 81, 849-56		12
412	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6578-6584	5.9	31
411	Anti-infective Dosing for Obese Adult Patients: A Focus on Newer Drugs to Treat Methicillin-resistant Staphylococcus aureus Acute Bacterial Skin and Skin Structure Infections. 2016 , 38, 2032-44		10
410	Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. 2016 , 72, 1343-1352		4
409	Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. 2016 , 82, 1517-1527		15
408	Introduction. 2016 , 1-12		
407	Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics. 2016 , 12, 1		12
406	HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6050-9	5.9	16
405	Does Weight Impact Anidulafungin Pharmacokinetics?. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1289-1294	6.2	13
404	Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 1830-3	5.9	11

403	Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. 2016 , 54, 120-130		29
402	Determination of a suitable voriconazole pharmacokinetic model for personalised dosing. 2016 , 43, 165-77		9
401	Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 833-847	6.2	58
400	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 723-33	6.2	27
399	James Lean Body Weight Formula Is Not Appropriate for Determining CT Contrast Media Dose in Patients with High Body Mass Index. 2016 , 278, 956-7		14
398	Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. 2016 , 75, 1363-6		29
397	Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 617-20	5.9	11
396	Evaluation of Lean Body Weight Equation by Dual-Energy X-Ray Absorptiometry Measures. 2017 , 41, 392-397		8
395	Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 77-90	6.2	28
394	Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen. 2017 , 17, 177-187		23
393	Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	4
392	Pharmacokinetics of Clindamycin in Obese and Nonobese Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	22
391	Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. 2017 , 37, 361-378		20
390	Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. 2017 , 72, 639-667		20
389	Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer. 2017 , 79, 587-594		2
388	Practical dosing of propofol in morbidly obese patients. 2017 , 64, 449-455		5
387	A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. 2017 , 83, 1713-1722		8
386	Optimal propofol induction dose in morbidly obese patients: A randomized controlled trial comparing the bispectral index and lean body weight scalar. 2017 , 64, 471-479		16

385	Propofol induction: normalizing the dose in morbidly obese patients. 2017 , 64, 456-460		6
384	Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. 2017 , 72, 1441-1449		25
383	Individualising the dose of allopurinol in patients with gout. 2017 , 83, 2015-2026		13
382	A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. 2017 , 73, 981-990		11
381	Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients. 2017 , 83, 823-835		23
380	Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	20
379	Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia. 2017 , 118, 415-423		15
378	Administration of rocuronium based on real body weight versus fat-free mass in patients with lymphedema. 2017 , 45, 2072-2077		
377	Allometric size: The scientific theory and extension to normal fat mass. 2017 , 109S, S59-S64		69
376	No role for patient body weight on renal function assessment for drug dosing. 2017 , 72, 1802-1811		3
375	The Predictive Value of Early In-Treatment F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer. 2017 , 58, 1243-1248		13
374	Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 1543-1554	6.2	59
373	Videolaryngoscopy or fibreoptic bronchoscopy for awake intubation of bariatric patients with predicted difficult airways - a randomised, controlled trial. 2017 , 72, 538-539		12
372	Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. 2017 , 72, 54-61		39
371	A Population Pharmacokinetic Model for Cr EDTA to Estimate Renal Function. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 671-678	6.2	2
370	What is the best size predictor for dose in the obese child?. 2017 , 27, 1176-1184		36
369	The impact of body weight on rivaroxaban pharmacokinetics. 2017 , 1, 180-187		29
368	Methodological Study of Vancomycin Dosing in Elderly Patients Using Actual Serum Creatinine Versus Rounded Serum Creatinine. 2017 , 17, 435-440		7

367	Pharmacokinetic-Guided Dosing of New Oral Cancer Agents. 2017 , 57 Suppl 10, S78-S98		19
366	Anaesthesia in the obese patient. 2017 , 18, 472-476		2
365	Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	27
364	Drug Dosing in Obese Children: Challenges and Evidence-Based Strategies. 2017 , 64, 1417-1438		11
363	Ideal Body Weight Is Not Really Ideal. 2017 , 127, 1043-1044		
362	Disposition of Remifentanyl in Obesity: A New Pharmacokinetic Model Incorporating the Influence of Body Mass. 2017 , 126, 1019-1032		16
361	An Allometric Model of Remifentanyl Pharmacokinetics and Pharmacodynamics. 2017 , 126, 1005-1018		51
360	Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	16
359	Population pharmacokinetics and analgesic potency of oxycodone. 2017 , 83, 314-325		27
358	Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients. 2017 , 57, 356-368		16
357	Understanding and applying pharmacometric modelling and simulation in clinical practice and research. 2017 , 83, 247-254		53
356	Existing equations to estimate lean body mass are not accurate in the critically ill: Results of a multicenter observational study. 2017 , 36, 1701-1706		14
355	Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 525-536	6.2	8
354	A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. 2017 , 73, 71-78		10
353	Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	22
352	Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	8
351	Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. 2017 , 72, 3131-3140		13
350	Pharmacokinetic variability due to environmental differences. 2017 , 25, 59-62		3

349	Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. 2017 , 9,	14
348	Novel Methods for Measuring Depth of Anesthesia by Quantifying Dominant Information Flow in Multichannel EEGs. 2017 , 2017, 3521261	2
347	Sugammadex ED90 dose to reverse the rocuronium neuromuscular blockade in obese patients. 2017 , 44, 41-45	1
346	Drug dosing in obese adults. 2017 , 40, 189-193	43
345	Risk stratification using lean body mass in patients undergoing transcatheter aortic valve replacement. 2018 , 92, 1365-1373	6
344	Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning. 2018 , 25, 14-20	26
343	Patient-specific lean body mass can be estimated from limited-coverage computed tomography images. 2018 , 39, 521-526	
342	Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9 4
341	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. 2018 , 67, 34-41	56
340	Determinants of amikacin first peak concentration in critically ill patients. 2018 , 32, 669-677	5
339	Dexmedetomidine metabolic clearance is not affected by fat mass in obese patients. 2018 , 120, 969-977	15
338	The Effect of New Formulas for Lean Body Mass on Lean-Body-Mass-Normalized SUV in Oncologic F-FDG PET/CT. 2018 , 46, 253-259	3
337	Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery. 2018 , 131, 211-217	5
336	Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. 2018 , 193, 102-108.e1	21
335	The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients. 2018 , 28, 1997-2005	6
334	Effect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessment. 2018 , 127, 865-872	10
333	Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. 2018 , 14, 275-285	66
332	A novel genomic signature predicting FDG uptake in diverse metastatic tumors. 2018 , 8, 4	3

331	Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. 2018 , 19, 17-29		11
330	Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	6
329	A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 781-795	6.2	9
328	Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	14
327	Pantoprazole pharmacokinetics in obese children: normalized to lean or ideal weight?. 2018 , 198, 327		
326	In reply: Optimal propofol induction dose in morbidly obese patients: bispectral index guidance is not the answer. 2018 , 65, 963-964		
325	Endocrine Disorders and Maxillofacial Surgery. 2018 , 289-302		
324	Development and Prospective Federal State-Wide Evaluation of a Device for Height-Based Dose Recommendations in Prehospital Pediatric Emergencies: A Simple Tool to Prevent Most Severe Drug Errors. 2018 , 22, 252-259		14
323	Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	14
322	Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia. 2018 , 12, 33-43		11
321	Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic-pharmacodynamic study. 2018 , 84, 310-319		13
320	Relation Between TRCA Complication Rates and Peak ACT Levels Stratified According to the BMI Tertiles. 2018 , 69, 400-405		
319	Dosing in Obese Critically Ill Patients. 2018 , 47-72		1
318	Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 831-841	6.2	3
317	Reliability of body-weight scalars on the assessment of propofol induction dose in obese patients. 2018 , 62, 464-473		2
316	Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 601-611	6.2	18
315	Abdominal CT: a radiologist-driven adjustment of the dose of iodinated contrast agent approaches a calculation per lean body weight. 2018 , 2, 41		16
314	Perioperative management of the obese ambulatory patient. 2018 , 31, 693-699		3

313	Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria. 2018 , 5, 35	12
312	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. 2018 , 13, 641-648	8
311	Drug Compartments and Body Systems. 45-52	
310	Normalised lean weight and drug doses for obese patients. 2018 , 73, 1444	0
309	Pharmacokinetics of anaesthetic drugs at extremes of body weight. 2018 , 18, 364-370	5
308	Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. 2018 , 13, e0203054	36
307	Lean Body Weight-Tailored Iodinated Contrast Injection in Obese Patient: Boer versus James Formula. 2018 , 2018, 8521893	17
306	Effects of Serum Albumin, Calcium Levels, Cancer Stage and Performance Status on Weight Loss in Parathyroid Hormone-Related Peptide Positive or Negative Patients with Cancer. 2018 , 33, 97-104	0
305	Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. 2018 , 121, 559-566	7
304	Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. 2018 , 73, 2104-2111	7
303	Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies. 2018 , 38, 673-693	5
302	Advances in pharmacokinetic modeling: target controlled infusions in the obese. 2018 , 31, 415-422	4
301	Performance of In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. 2018 , 45, 2062-2070	10
300	First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. 2018 , 123, 416-428	3
299	Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects. 2018 , 7, 573-580	0
298	Characterization of cardiovascular depression effect for propofol during anesthesia induction period on morbidly obese patients. 2018 , 106, 618-623	3
297	[Drugs for intravenous induction of anesthesia: barbiturates]. 2018 , 67, 535-552	4
296	Author's Reply to Reith: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen". <i>Clinical Pharmacokinetics</i> , 2018 , 57, 897-899	6.2

295	Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. 2018 , 20, 365-374	15
294	A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents. 2018 , 20, 483-495	10
293	A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim. 2018 , 20, 91	8
292	Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis. 2018 , 84, 2242-2251	4
291	Induction of anaesthesia with propofol according to the adjusted ideal body mass in obese and non-obese patients: an observational study. 2019 , 25, 6-11	
290	Total Intravenous Anesthesia and Target-Controlled Infusion. 2019 , 177-198.e3	
289	Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma. 2019 , 54, 2081-2087	4
288	A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. 2020 , 26, 570-580	6
287	Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics. 2019 , 11,	3
286	Propofol Sedation for Intra-gastric Balloon Removal: Looking for the Optimal Body Weight Descriptor. 2019 , 29, 3882-3890	4
285	Image quality evaluation in a modern PET system: impact of new reconstructions methods and a radiomics approach. 2019 , 9, 10640	9
284	Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. 2019 , 28, 1262-1265	
283	Gender medicine and oncology: report and consensus of an ESMO workshop. 2019 , 30, 1914-1924	47
282	Imaging of Bone Perfusion and Metabolism in Subjects Undergoing Total Ankle Arthroplasty Using F-Fluoride Positron Emission Tomography. 2019 , 40, 1351-1357	4
281	Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients. 2019 , 19, 180	1
280	Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures. 2019 , 1, 100051	
279	Levothyroxine Dosing After Thyroidectomy Should Be Determined by Both BMI and Body Weight. 2019 , 31, 470-471	
278	Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9 11

277	Evaluation of Thyroid Hormone Replacement Dosing in Overweight and Obese Patients After a Thyroidectomy. 2019 , 29, 1558-1562		8
276	Thoracic Anesthesia for Morbidly Obese Patients and Obese Patients with Obstructive Sleep Apnea. 2019 , 545-559		
275	Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 815-826	6.2	13
274	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	6
273	Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. 2019 , 85, 924-934		6
272	Anestesia del paciente adulto obeso. 2019 , 45, 1-12		
271	Differential clusters of modifiable risk factors for impaired fasting glucose impaired glucose tolerance in adults 50 years of age and older. 2019 , 10, 2040622319854239		1
270	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. 2019 , 36, 112		8
269	Propofol pharmacokinetic model and lean body weight scalar for dose estimation in morbid obesity. 2019 , 123, e159-e160		2
268	Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration. 2019 , 14, e0216801		2
267	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1333-1343	6.2	5
266	The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. 2019 , 9, 6447		26
265	Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data. 2019 , 75, 785-794		6
264	Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis. 2019 , 85, 1946-1956		6
263	Drug-Nutrition Interactions and the Brain: It's Not All in Your Head. 2019 , 8, 92-98		5
262	Gender, cholinesterase, platelet count and red cell count are main predictors of peripheral blood stem cell mobilization in healthy donors. 2019 , 114, 275-282		1
261	Gestione anestetica del paziente adulto obeso. 2019 , 24, 1-11		
260	Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies. <i>Journal of Anesthesia</i> , 2019 , 33, 381-389	2.2	2

259	Pharmacokinetics-Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease. 2019 , 255-284	
258	Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial. 2019 , 54, 1482-1488	7
257	Dosing Antifungals in Obesity: a Literature Review. 2019 , 13, 21-32	3
256	Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). 2019 , 21, 1493-1497	17
255	Prescribing Patterns of Continuous Infusions in Nonobese versus Obese Children Admitted to the Pediatric Intensive Care Unit. 2019 , 8, 226-232	
254	The appropriate whole body metric for calculating standardised uptake value and the influence of sex. 2019 , 40, 3-7	4
253	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. 2019 , 11,	17
252	Ankle Biters. 2019 , 111-123	0
251	Big Can Be Beautiful!. 2019 , 132-138	
250	Population Pharmacokinetic-Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS). 2019 , 60, 617	5
249	The Pharmacodynamic Effects of a Dopamine-Somatostatin Chimera Agonist on the Cardiovascular System. 2019 , 74, 128-136	2
248	Covariate Analysis in Clinical Anaesthesia. 2019 , 40-62	
247	Physiology and Pharmacology of Obesity, Pediatrics, and the Elderly. 2019 , 91-112	1
246	Inhibition of Mevalonate Pathway Prevents Adipocyte Browning in Mice and Men by Affecting Protein Prenylation. 2019 , 29, 901-916.e8	37
245	Optimising infliximab induction dosing for patients with ulcerative colitis. 2019 , 85, 782-795	15
244	Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. 2019 , 74, 978-985	8
243	Improving Drug Use and Dosing in Chronic Kidney Disease. 2019 , 250-272.e5	
242	Population-based volume kinetics of Ringer's lactate solution in patients undergoing open gastrectomy. 2019 , 40, 710-716	7

241	Acetaminophen pharmacokinetics in severely obese adolescents and young adults. 2019 , 29, 20-26		8
240	The translation of age-related body composition findings from rodents to humans. 2019 , 73, 172-178		9
239	Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. 2019 , 14, e12459		11
238	Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections. 2020 , 9, 175-188		5
237	Population pharmacokinetic modeling and simulation of HPPH in Chinese patients with esophageal carcinoma. 2020 , 50, 170-177		1
236	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 371-382	6.2	4
235	Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 475-483	6.2	3
234	Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. 2020 , 70, 2213-2215		9
233	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. 2020 , 86, 303-317		18
232	Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. 2020 , 47, 1527-1537		9
231	Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients. 2020 , 86, 933-943		3
230	Controversies in Perioperative Antimicrobial Prophylaxis. 2020 , 132, 586-597		6
229	A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. 2020 , 31, 161-174		20
228	Practical Estimation of Ideal Body Weight and Normalized Lean Weight. 2020 , 30, 2437-2438		1
227	The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. 2020 , 294, 647-657		23
226	Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. 2020 , 5, 189-198		7
225	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. 2020 , 22, 223		5
224	Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa. 2020 , 75, 3260-3268		2

223	Comparative pharmacokinetics of the three echinocandins in ICU patients. 2020 , 75, 2969-2976		3
222	Incorporating nonlinear kinetics to improve predictive performance of population pharmacokinetic models for ciclosporin in adult renal transplant recipients: A comparison of modelling strategies. 2020 , 153, 105471		2
221	Basic pharmacokinetics. 2020 , 895-904		1
220	Comment on: "An Extension of Janmahasatian's Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities". <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1313-1314	6.2	1
219	Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. 2020 , 8, e00684		2
218	Radiologic Assessment of Groin Lymph Nodes in Pelvic Malignancies. 2020 , 30, 947-953		3
217	Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections. 2020 , 75, 2933-2940		1
216	Clofazimine pharmacokinetics in patients with TB: dosing implications. 2020 , 75, 3269-3277		11
215	Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy. 2020 , 153, 105484		0
214	Opioid-free anesthesia with a mixture of dexmedetomidine, ketamine, and lidocaine in one syringe for surgery in obese patients. 2020 , 48, 300060520967830		2
213	The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients. 2020 , 46, 2147-2153		3
212	Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. 2020 , 75, 3286-3292		1
211	A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. 2020 , 9,		5
210	Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. 2020 , 24, 315		16
209	Cold-Activated Brown Adipose Tissue is Associated with Less Cardiometabolic Dysfunction in Young Adults with Obesity. 2020 , 28, 916-923		10
208	Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease. 2020 , 158, 350-358		6
207	Relative blood loss in forensic medicine-do we need a change in doctrine?. 2020 , 134, 1123-1131		1
206	An Extension of Janmahasatian's Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1161-1170	6.2	4

205	Sodium Bicarbonate Supplementation and Urinary TGF-1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial. 2020 , 15, 200-208		10
204	Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections. 2020 , 11, 829		10
203	Authors' Reply to Friesen: "An Extension of Janmahasatian's Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities". <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1315	6.2	3
202	Individualized Whole-Body Vibration: Neuromuscular, Biochemical, Muscle Damage and Inflammatory Acute Responses. 2020 , 18, 1559325820931262		2
201	Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics. 2020 , 55, 1862-1864		1
200	Implications for IV posaconazole dosing in the era of obesity. 2020 , 75, 1006-1013		10
199	Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. 2020 , 107, 1023-1033		15
198	Guidelines on muscle relaxants and reversal in anaesthesia. 2020 , 39, 125-142		29
197	Normalization by bone volume instead of body weight or lean body mass may be better for quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. 2020 , 47, 1349-1350		2
196	Standardized image quality for Ga-DOTA-TATE PET/CT. 2020 , 10, 27		4
195	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. 2020 , 12,		3
194	Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project. 2020 , 26, 384-400		14
193	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. 2021 , 87, 106-118		7
192	Assessment of Kidney Function in Patients With Extreme Obesity: A Narrative Review. 2021 , 55, 80-88		2
191	Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. 2021 , 27, 579-587		1
190	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 191-203	6.2	3
189	Median Effective Dose of Lidocaine for the Prevention of Pain Caused by the Injection of Propofol Formulated with Medium- and Long-Chain Triglycerides Based on Lean Body Weight. 2021 , 22, 1246-1252		0
188	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. 2021 , 87, 2602-2613		4

187	Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	4
186	Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. 2021 , 10, 622-633		3
185	Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies. 2021 , 77, 727-733		2
184	Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children. 2021 , 87, 2847-2854		1
183	Estimation of Body Fat Percentage for Clinical Pharmacokinetic Studies in Children. 2021 , 14, 509-517		2
182	Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 17-51	6.2	9
181	Population pharmacokinetics of propofol in neonates and infants: Gestational and postnatal age to determine clearance maturation. 2021 , 87, 2089-2097		1
180	Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization. 2021 , 87, 1359-1368		1
179	A retrospective study comparing creatinine clearance estimation using different equations on a population-based cohort. 2021 , 18, 5680-5691		0
178	Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol?. 2021 , 48, 305-317		0
177	Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. 2021 , 76, 1269-1272		1
176	Body position and the effectiveness of mask ventilation in anaesthetised paralysed obese patients: A randomised cross-over study. 2021 , 38, 825-830		1
175	A method for evaluation of patient-specific lean body mass from limited-coverage CT images and its application in PERCIST: comparison with predictive equation. 2021 , 8, 12		0
174	Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. 2021 , 46, 249-263		1
173	Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Obesity. 2021 , 109, 942-951		0
172	Evaluation of SUVlean consistency in FDG and PSMA PET/MR with Dixon-, James-, and Janma-based lean body mass correction. 2021 , 8, 17		1
171	Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. 2021 , 25, 77		1
170	Acute Nutritional Ketosis and Its Implications for Plasma Glucose and Glucoregulatory Peptides in Adults with Prediabetes: A Crossover Placebo-Controlled Randomized Trial. 2021 , 151, 921-929		3

169	Towards Personalised Contrast Injection: Artificial-Intelligence-Derived Body Composition and Liver Enhancement in Computed Tomography. 2021 , 11,		2
168	Factor VIII concentrate dosing with lean body mass, ideal body weight and total body weight in overweight and obesity: A randomized, controlled, open-label, 3 TB crossover trial. 2021 , 27, 351-357		1
167	The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. 2021 , 87, 3776-3789		0
166	Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin. 2021 , 38, 381-395		4
165	Tc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle. 2021 , 11, 22		2
164	Dosing of neuromuscular blocking agents in patients with obesity: A narrative review. 2021 , 49, 98-104		4
163	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1201-1215	6.2	2
162	Population pharmacokinetics of ropivacaine used for local infiltration anaesthesia during primary total unilateral and simultaneous bilateral knee arthroplasty. 2021 , 126, 872-880		0
161	Development of a new pharmacokinetic model for target-concentration controlled infusion of cefoxitin as a prophylactic antibiotic in colorectal surgical patients. 2021 ,		0
160	Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid. 2021 ,		1
159	Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. 2021 , 10, 4781-4789		1
158	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ�Italiana Endocrinologia (SIE)/Societ�Italiana Farmacologia (SIF) multidisciplinary consensus position paper. 2021 , 6, 100153		3
157	Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by F-FDG total-body PET/CT imaging?. 2021 , 1		4
156	Model-Informed Optimization of a Pediatric Clinical Pharmacokinetic Trial of a New Spironolactone Liquid Formulation. 2021 , 13,		1
155	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. 2021 ,		1
154	Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System. 2021 , 61, 1182-1194		3
153	Body composition and mortality in patients undergoing endovascular treatment for peripheral artery disease. 2021 , 36, 1830-1840		3
152	Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. 2021 , 19, 1896-1906		4

151	Socioeconomic position and body composition in childhood in high- and middle-income countries: a systematic review and narrative synthesis. 2021 , 45, 2316-2334		3
150	Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. 2021 ,		2
149	A Model-Based Approach to Assess Unstable Creatinine Clearance in Critically Ill Patients. 2021 , 110, 1240-1249		0
148	Life course socioeconomic position and body composition in adulthood: a systematic review and narrative synthesis. 2021 , 45, 2300-2315		5
147	Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with <i>Strongyloides Stercoralis</i> : Support for a Fixed-Dose Treatment Regimen. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
146	Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanyl. 2021 , 74, 478-487		
145	Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients. 2021 , 12, 727170		1
144	Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics. 2021 , 13,		0
143	Inpatient repeatability of background F-FDG uptake on PET/CT. 2021 , 11, 4172-4180		1
142	Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0138121	5.9	1
141	Evaluation of amoxicillin, metronidazole and gentamicin dosage regimens for use in antibiotic prophylaxis in colorectal surgery. 2021 , 76, 3212-3219		
140	Drug dosage in patients with obesity: Investigation of lean body mass. 2021 , 310057X211034520		1
139	Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. 2021 , 205, 120-127		4
138	Population pharmacokinetics of oxycodone: Premature neonates to adults. 2021 , 31, 1332-1339		6
137	Development of a new pharmacokinetic model for target-concentration controlled infusion of vancomycin in critically ill patients. 2021 ,		0
136	Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients. 2021 , 10,		
135	Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. 2021 , 121, 731-740		3
134	Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. 2021 , 11,		3

133	Nonlinear Mixed Effects Models: Practical Issues. 2011 , 303-358		2
132	The Impact of Obesity on Pharmacokinetics and Dosing of Leukemia Chemotherapy. 2012 , 97-127		1
131	Applied Pharmacometrics in the Obese Population. 2014 , 161-187		3
130	How to Select a PK/PD Model. 2017 , 171-187		1
129	The Development and Regulation of Commercial Devices for Target-Controlled Drug Infusion. 2017 , 9-29		1
128	Pharmacokinetics and Pharmacodynamics in the Pediatric Patient. 2017 , 441-516		1
127	How Should Obesity be Measured and How Should Anesthetic Drug Dosage be Calculated?. 2013 , 15-30		3
126	Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 875-884	6.2	6
125	Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis. 2021 , 76, 1019-1024		2
124	Remifentanyl Dosing at Extremes of Body Weight. 2017 , 126, 993-994		3
123	Low-dose F-FDG TOF-PET/MR for accurate quantification of brown adipose tissue in healthy volunteers. 2020 , 10, 5		2
122	Results from extended lymphadenectomies with [In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer. 2020 , 10, 17		11
121	Hormonal and neuromuscular responses to mechanical vibration applied to upper extremity muscles. 2014 , 9, e111521		29
120	Propofol clearance in morbidly obese children and adolescents: influence of age and body size. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 543-51	6.2	13
119	A Pilot Study of FDG-PET/CT in Polycythemia Vera Using Global Analysis Techniques. 2020 , 8, 64-68		1
118	Assessment of phase-lag entropy, a new measure of electroencephalographic signals, for propofol-induced sedation. 2019 , 72, 351-356		3
117	THE EFFECT OF OBESITY ON DOSE OF DEXMEDETOMIDINE WHEN ADMINISTERED WITH FENTANYL DURING POSTOPERATIVE MECHANICAL VENTILATION--RETROSPECTIVE. 2015 , 61, 38-46		2
116	Drug-nutrition interactions. 2021 ,		

- 115 Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. **2021**, 13, 1
- 114 Development and validation of a length- and habitus-based method of ideal and lean body weight estimation for critically ill adults requiring urgent weight-based medical intervention.
- 113 Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients. **2021**, 1
- 112 Is SUV Corrected for Lean Body Mass Superior to SUV of Body Weight in Ga-PSMA PET/CT?. **2021**, 30, 144-149
- 111 Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates. **2021**, 1 2
- 110 Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. **2021**, 21, 407-417 0
- 109 Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. **2021**, 46, 807-816 1
- 108 Anaesthesia in Maternal Obesity. **2012**, 231-245 1
- 107 Should Anesthesiologists Managing Morbidly Obese Patients Receive Special Education and Training?. **2013**, 3-13
- 106 Anesthetic Considerations. **2015**, 85-96
- 105 Population Pharmacokinetics of Metformin in Mexican Patients with Type 2 Diabetes Mellitus. **2015**, 11, 632-637 0
- 104 Is Dose Adjustment Based on Several Factors of Body Size Descriptors Effective for Prevention of Thrombocytopenia by Linezolid Therapy in Hemodialysis Patients?. **2016**, 07, 417-423
- 103 Intravenous Anesthesia in Obese Patients. **2017**, 429-440
- 102 TCI in Special Patients Groups: The Elderly and Obese. **2017**, 571-578
- 101 Predictive performance of target controlled infusion of propofol-MCT/LCT using the modified Marsh and Schnider models: a simulation study. **2017**, 12, 117-122
- 100 Comparison of Appropriate Piperacillin/Tazobactam Doses in Korean Obese Patients with Cancer Based on Different Body Size Descriptor Equations in a Tertiary Care Hospital. **2017**, 27, 83-91
- 99 Ergonomic Evaluation of Physical Workload Among Steelworkers. **2019**, 208-216
- 98 SUV calculation in breast cancer: which normalization should be applied when using 18F-FDG PET?. **2019**, 63, 399-407 0

97	Toward Reliable Uptake Metrics in Large Vessel Vasculitis Studies. 2021 , 11,	2
96	Drug-Nutrition Interactions in Infectious Diseases. 2021 , 367-410	2
95	Thoracic Anesthesia in the Morbidly Obese Patient: Obstructive Sleep Apnea. 2022 , 713-728	
94	Anesthetic Considerations. 2020 , 89-101	
93	Incorporating Nonlinear Kinetics to Improve the Predictive Performance of Population Pharmacokinetic Models for Cyclosporin in Adult Renal Transplant Recipients: A Comparison of Modelling Strategies.	
92	Weight Considerations. 2020 , 593-608	
91	Factors Affecting Time-Varying Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective. 2021 , 38, 1873	2
90	Relationship between Adverse Events and AUC in Japanese Patients with Multiple Myeloma Receiving High-dose Melphalan. 2020 , 46, 396-402	
89	New gender-specific formulae for estimating extracellular fluid volume from height and weight in adults. 2021 , 42, 58-62	
88	Drug dosing in renal disease. 2011 , 32, 69-73	42
87	Thermal balance of spinal cord injured divers during cold water diving: A case control study. 2020 , 50, 256-263	1
86	Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?. 2021 , 8, 725346	
85	The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study. 2021 ,	3
84	Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno-venous haemofiltration. 2021 ,	3
83	Evaluation and enhancement of standard equations for renal function estimation in individuals with components of metabolic disease. 2021 , 22, 389	0
82	Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2 0
81	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder.. 2021 , 308, 114354	
80	Thermal balance of spinal cord injured divers during cold water diving: A case control study. 2020 , 50, 256-263	1

79	Utility of the C-pantoprazole breath test as a CYP2C19 phenotyping probe for children.. 2022,		
78	Comparison of two pharmacokinetic-pharmacodynamic models of rocuronium bromide during profound neuromuscular block: analysis of estimated and measured post-tetanic count effect.. 2022,		0
77	Allometric Scaling in Pharmacokinetic Studies in Anesthesiology.. 2022,		0
76	Comparison of ten predictive equations for estimating lean body mass with dual-energy X-ray absorptiometry in older patients.. 2022, 20210378		0
75	A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV. 7, 72		
74	Comparing opioid free general anesthesia to traditional balanced general anesthesia regarding achievement of enhanced recovery in laparoscopic bariatric surgeries. 2022, 14,		0
73	Characterizing Pharmacokinetics in Children With Obesity-Physiological, Drug, Patient, and Methodological Considerations.. 2022, 13, 818726		2
72	Population Pharmacokinetic Modelling of Acetaminophen and Ibuprofen: the Influence of Body Composition, Formulation and Feeding in Healthy Adult Volunteers.. 2022, 1		3
71	An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients.. <i>Clinical Pharmacokinetics,</i> 2022, 1	6.2	1
70	Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. <i>Clinical Pharmacokinetics,</i> 2021, 1	6.2	1
69	The expected advantage of administering prophylactic antibiotics using target- concentration controlled infusion: Development of a new pharmacokinetic model of cefazolin.. 2022,		
68	Image_1.pdf. 2020,		
67	Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization.. <i>Antimicrobial Agents and Chemotherapy,</i> 2022, e0169621	5.9	1
66	Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?. 2021, 8, 725346		1
65	OUP accepted manuscript.		0
64	Population pharmacokinetics of omeprazole in obese and normal-weight adults.. 2022,		1
63	Sex and gender differences in anticancer treatment toxicity - a call for revisiting drug dosing in oncology.. 2022,		1
62	Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn. 2022, 11, 618		

61	Artificial intelligence-based PET denoising could allow a two-fold reduction in [F]FDG PET acquisition time in digital PET/CT.. 2022 ,		0
60	Effects Of Oxandrolone On Lean Body Mass (Lbm) In Severe Burn Patients: A Randomized, Double Blind, Placebo-Controlled Trial.. 2022 , 35, 55-61		
59	High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients. <i>Antimicrobial Agents and Chemotherapy</i> ,	5.9	0
58	Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. <i>Antimicrobial Agents and Chemotherapy</i> ,	5.9	
57	Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical Pharmacokinetics</i> ,	6.2	0
56	Population Pharmacokinetics of Vancomycin in Pregnant Women. 13,		1
55	Drug Disposition in Subjects with Obesity: The Research Work of Darrell R. Abernethy.		2
54	Important lack of difference in tacrolimus and mycophenolic acid pharmacokinetics between Aboriginal and Caucasian kidney transplant recipients. <i>Nephrology</i> ,	2.2	
53	A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice. <i>Journal of Anesthesia</i> ,	2.2	0
52	Does Monitoring Total and Free Polymyxin 'B1 Plasma Concentrations Predict Polymyxin 'B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients. <i>Infectious Diseases and Therapy</i> ,	6.2	0
51	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. <i>Antimicrobial Agents and Chemotherapy</i> ,	5.9	0
50	Rapid Standardized CT-Based Method to Determine Lean Body Mass SUV for PET A Significant Improvement Over Prediction Equations. <i>Frontiers in Oncology</i> , 12,	5.3	
49	The Influence of Age, Sex, and Type of Exercise on the Efficacy of Creatine Supplementation on Lean Body Mass: A Systematic Review and Meta-analysis of Randomized Clinical Trials. <i>Nutrition</i> , 2022 , 111791	4.8	
48	Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis. <i>Biomedicines</i> , 2022 , 10, 1575	4.8	3
47	Pitfalls and pearls with drug dosing in the critically ill obese patient: 10 statements to guide ICU practitioners. <i>Journal of Critical Care</i> , 2022 , 71, 154105	4	
46	Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.		0
45	Predicting Tacrolimus Exposure in Kidney Transplanted Patients Using Machine Learning. 2022 ,		0
44	Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels.		0

- 43 Development and Validation of a Length- and Habitus-Based Method of Ideal and Lean Body Weight Estimation for Adults Requiring Urgent Weight-Based Medical Intervention. ○
- 42 Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis. **2022**, ○
- 41 Estimating Lean Body Weight in Adults With the PAWPER XL-MAC Tape Using Actual Measured Weight as an Input Variable. **2022**, ○
- 40 Effect of Laparoscopic Sleeve Gastrectomy on the Pharmacokinetics of Oral Omeprazole Using a Population Approach. **2022**, 14, 1986 ○
- 39 Anesthésie Intra Veineuse □Objectif de Concentration chez l'obèse. **2022**, ○
- 38 Factors Affecting Plasma Concentrations. **2022**, 249-274 ○
- 37 A standardised protocol for measuring bioelectrical impedance in green turtles (*Chelonia mydas*). 1
- 36 Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma. ○
- 35 Population Pharmacokinetics and Dosing Simulations of Intravenous Oxycodone for Perioperative Pain Relief in Adult Surgical Patients with Obesity. ○
- 34 Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients. ○
- 33 Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist. ○
- 32 Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes. 1-18 ○
- 31 Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multidrug-resistant Gram-negative bacterial infections. **2022**, 106693 ○
- 30 Performance of different body weights in the Cockcroft-Gault equation in critically ill patients with and without augmented renal clearance: A multicenter cohort. ○
- 29 Abnormal [¹⁸F]FDG uptake in liver and adipose tissue: a potential imaging biomarker for cancer-associated cachexia. ○
- 28 The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics. ○
- 27 EFOMP protocol quality controls in PET/CT and PET/MR. **2023**, 105, 102506 ○
- 26 Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation. **2022**, 31, 096368972211433 ○

25	[18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study.	0
24	Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis. 7, 72	0
23	Challenges and Possible Solutions to Direct-Acting Oral Anticoagulants (DOACs) Dosing in Patients with Extreme Bodyweight and Renal Impairment.	0
22	Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects.	0
21	Penetration of Vancomycin into Noninfected Bone in Patients Undergoing Total Joint Arthroplasty Evaluated by a Minimal Physiologically Based Population Pharmacokinetic Modeling Approach.	0
20	Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.	0
19	Pharmacokinetics of dexmedetomidine in pediatric patients undergoing cardiac surgery with cardiopulmonary bypass.	0
18	Der Einfluss von Geschlecht auf Gesundheit, Krankheit und Prävention. 2023, 97-110	0
17	Comprehensive Guidance for Antibiotic Dosing in Obese Adults: 2022 Update.	0
16	Impact of patient's habitus on image quality and quantitative metrics in 18F-FDG PET/CT images. 2023, 109, 102584	0
15	Consistent methods for fat-free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults. 2023, 12, 401-412	1
14	Development and validation of anthropometric predictive equations that estimate the total body water and fat-free mass in Tunisian adults. 2023, 77, 447-453	0
13	Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. 2023, 31,	0
12	Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.	0
11	Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight. 2023, 61, 106751	0
10	Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD. 2023, 12, 1642	1
9	Estimation of Glomerular Filtration Rate in Obese Patients: Utility of a New Equation. 2023, 15, 1233	0
8	Overcorrection and undercorrection with fixed dosing of bolus hypertonic saline for symptomatic hyponatremia. 2023, 188, 322-330	0

- 7 Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable?. **2023**, Publish Ahead of Print,
- 6 Pediatric Obesity. **2017**, 1201-1209.e3
- 5 Perioperative Acetaminophen Dosing in Obese Children. **2023**, 10, 625
- 4 Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population.
- 3 Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents.
- 2 Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis.
- 1 Connecting the mechanisms of tumor sex differences with cancer therapy.